MIAMI LAKES, FL--(Marketwired - Nov 15, 2013) - Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) announced today further advancements of its technology partnership with Macular Health, LLC.

Fuse Science® is a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. As previously reported, Macular Health has partnered with Fuse Science® to develoop new patent pending sublingual drop formulations to enhance treatment for Age-Related Macular Degeneration ("AMD"). AMD is a medical condition which usually affects older adults and results in a loss of vision because of damage to the retina.

Beginning tomorrow, November 16th, and continuing through November 19th 2013, Macular Health will showcase the MacuDrop™ AREDS II Formula at the American Academy of Ophthalmology meeting. MacuDrop™ is designed to reduce the progression of AMD beyond current formulations by leveraging the proprietary sublingual technology of Fuse Science®. The partnership is actively focused on the commercialization of up to three new formulations to address AMD which is the leading cause of blindness in people over the age of 50.

About Age-Related Macular Degeneration
Macular degeneration is the leading cause of blindness in American adults. The condition, which is a breakdown of the macula of the eye, typically occurs during the aging process. Damage of the macula, caused by macular degeneration, increases the difficulty of seeing fine details clearly. Macular degeneration can make activities such as reading and threading a needle impossible. The ability to see both near and far is hindered by macular degeneration because damage to the macula causes blurriness and distortion of vision. There is no cure for macular degeneration, but there is hope of slowing vision loss with proper nutrition. For more information, visit www.macularhealth.com.

About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products and delivery technology company based in Miami Lakes, Florida. Fuse Science® holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. These rights include sublingual and transdermal delivery systems for bioactive agents that can, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science® technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science® is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For Fuse Science® news as it happens, follow @FuseScience on Twitter and Like "Fuse Science" on Facebook, www.facebook.com/FuseScience.

Get all Fuse Science® corporate updates sent directly to you; sign up for Fuse News Alerts in the Investor Relations section at www.fusescience.com.

For more information:
Fuse Science, Inc.
Investor Relations
Direct: (305) 503-3873, Ext. 2
Email: ir@fusescience.com